Compare · ARGX vs HUMA
ARGX vs HUMA
Side-by-side comparison of argenx SE (ARGX) and Humacyte Inc. (HUMA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and HUMA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.34B, about 339.7x HUMA ($157.0M).
- Over the past year, ARGX is up 54.7% and HUMA is down 69.0% - ARGX leads by 123.7 points.
- HUMA has been more active in the news (3 items in the past 4 weeks vs 2 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for HUMA).
- Company
- argenx SE
- Humacyte Inc.
- Price
- $858.23-2.08%
- $0.71+3.00%
- Market cap
- $53.34B
- $157.0M
- 1M return
- -4.38%
- -34.21%
- 1Y return
- +54.68%
- -68.98%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 2
- 3
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest HUMA
- Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
- Amendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.
- SEC Form SCHEDULE 13G filed by Humacyte Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Humacyte Inc.
- Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
- SEC Form 4 filed by Director Windham-Bannister Susan Richards
- SEC Form 4 filed by Director Constantino Michael T.
- SEC Form 4 filed by Director Wallace Max N.
- SEC Form 4 filed by President, CEO and Director Niklason Laura E
- SEC Form 4 filed by Director Sebelius Kathleen